Log in with your email address username.


Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Comment] Fibroblast growth factor 21 for non-alcoholic steatohepatitis

Non-alcoholic steatohepatitis is a form of fatty liver disease that is characterised by hepatic necroinflammation, progression of fibrosis, and a strong association with metabolic syndrome, and is increasing as a cause of morbidity and mortality. In the USA alone, 27 million people are anticipated to have non-alcoholic steatohepatitis by 2030, which is expected to cause 105 430 cases of decompensated cirrhosis, 12 240 cases of hepatocellular carcinoma, and 78 300 deaths from liver-associated causes annually.